Skip to contentG
GeneDx Holdings Corp.
G
WGSGeneDx Holdings Corp. Q3 2023 · 10-Q
Revenue$53.30M$53.30M−36.0% vs Q3 2022 Net Income-$42.29M-$42.29MN/M vs Q3 2022 EPS Diluted-$1.64-$1.64N/M vs Q3 2022 Gross Profit$25,259,000+86.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GeneDx Holdings Corp. · CIK 1818331 · Engraved from SEC EDGAR
Operating Cash Flowderived-$41,228,000N/M Free Cash Flowderived-$41,340,000N/M Margins · derivedGross margin47.4%+31.1 pt vs Q3 2022
Operating margin-80.6%+28.5 pt vs Q3 2022
Net margin-79.3%+13.9 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 3, 2023 · 34 d after period end